MENU
+Compare
ADIL
Stock ticker: NASDAQ
AS OF
Apr 17 closing price
Price
$0.69
Change
-$0.03 (-4.17%)
Capitalization
4.51M

ADIL Adial Pharmaceuticals Forecast, Technical & Fundamental Analysis

Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company... Show more

ADIL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for ADIL with price predictions
Apr 17, 2025

ADIL saw its Stochastic Oscillator leaves the overbought zone

The Stochastic Oscillator for ADIL moved out of overbought territory on April 11, 2025. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 33 similar instances where the indicator exited the overbought zone. In of the 33 cases the stock moved lower. This puts the odds of a downward move at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

ADIL moved below its 50-day moving average on April 10, 2025 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ADIL declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on April 07, 2025. You may want to consider a long position or call options on ADIL as a result. In of 107 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for ADIL just turned positive on April 02, 2025. Looking at past instances where ADIL's MACD turned positive, the stock continued to rise in of 44 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ADIL advanced for three days, in of 199 cases, the price rose further within the following month. The odds of a continued upward trend are .

ADIL may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.109) is normal, around the industry mean (13.444). P/E Ratio (0.000) is within average values for comparable stocks, (62.833). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.754). Dividend Yield (0.000) settles around the average of (0.026) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (250.783).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. ADIL’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ADIL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
ADIL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

ADIL is expected to report earnings to fall 42.86% to -5 cents per share on August 15

Adial Pharmaceuticals ADIL Stock Earnings Reports
Q2'23
Est.
$-0.06
Q1'23
Est.
$-0.10
Q4'22
Beat
by $0.05
Q3'22
Beat
by $0.06
Q2'22
Missed
by $0.01
The last earnings report on May 12 showed earnings per share of -10 cents, missing the estimate of -10 cents. With 18.50K shares outstanding, the current market capitalization sits at 4.51M.
A.I. Advisor
published General Information

General Information

a developer of medications to treat addiction and related disorders

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Pharmaceuticals Major
Address
4870 Sadler Road
Phone
+1 804 487-8196
Employees
7
Web
https://www.adialpharma.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
GME26.780.53
+2.02%
GameStop Corp
AAPL196.982.71
+1.39%
Apple
SPY526.410.75
+0.14%
SPDR® S&P 500® ETF
TSLA241.37-0.18
-0.07%
Tesla
BTC.X84450.805000-444.945300
-0.52%
Bitcoin cryptocurrency

ADIL and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, ADIL has been loosely correlated with VANI. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if ADIL jumps, then VANI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ADIL
1D Price
Change %
ADIL100%
-4.31%
VANI - ADIL
37%
Loosely correlated
+0.95%
CLYM - ADIL
34%
Loosely correlated
N/A
GDTC - ADIL
30%
Poorly correlated
+5.58%
VTVT - ADIL
28%
Poorly correlated
+4.68%
JAGX - ADIL
26%
Poorly correlated
-1.81%
More